"This has been a certain setback for the company and its shares, however, there may exist an opportunity hidden behind the negative publicity."
Yes. Go the the web page and read the press releases.
No ! I am getting the info direct from their company web page press releases. Don't get me wrong...this is not a $55.00 stock..yet... for several months...or so, but a $20 to $30 in 2 to 4 months is do'able. My son is a organic chemist and bio background.
Macdonald added, "We continue to believe that eravacycline can benefit patients with serious infections, particularly those caused by difficult-to-treat Gram-negative bacteria."
"We previously announced positive data from the IGNITE1 phase 3 clinical trial of eravacycline administered intravenously in complicated intra-abdominal infections which did meet its primary endpoint, demonstrating high cure rates in prevalent Gram-negative pathogens and a favorable safety profile."
$20.00 to $30.00 range in a couple of months when the other drugs have input towards the bottom line.